Core Viewpoint - Haohai Biological Technology (06826) announced the acquisition of the remaining 20% equity in Shenzhen New Industry Ophthalmic Technology Co., Ltd. for RMB 74 million, aiming to enhance its market position in the ophthalmic high-value consumables sector [1] Group 1: Acquisition Details - The acquisition agreement was signed on November 7, 2025, between Haohai's wholly-owned subsidiary Shanghai Haohai Pharmaceutical Technology and the sellers [1] - After the completion of this acquisition, the company will hold 100% equity in the target company [1] Group 2: Target Company Overview - The target company specializes in the manufacturing and sales of orthokeratology lenses and artificial lenses, as well as the distribution of various imported ophthalmic products in mainland China [1] - The company has been progressively entering the ophthalmic high-value consumables market since acquiring 60% and 20% stakes in 2016 and 2023, respectively [1] Group 3: Strategic Importance - The acquisition is expected to improve the management and operational efficiency of the target company, thereby enhancing the competitiveness of the company's ophthalmic products in the market [1] - The board believes that this acquisition aligns with the company's development needs and overall business strategy [1]